Collegium Pharmaceutical (NASDAQ:COLL – Get Free Report)‘s stock had its “neutral” rating reiterated by equities researchers at Piper Sandler in a research report issued to clients and investors on Friday,Benzinga reports. They presently have a $43.00 price target on the specialty pharmaceutical company’s stock, down from their prior price target of $45.00. Piper Sandler’s price [...]
Piper Sandler Reiterates Neutral Rating for Collegium Pharmaceutical (NASDAQ:COLL)
